Khalid F, Bodla Z, Gaddameedi S, Macasaet R, Yagnik K, Niaz Z
Curr Oncol. 2025; 32(2).
PMID: 39996908
PMC: 11854063.
DOI: 10.3390/curroncol32020108.
Sawa Y, Jia L, Krause H, Meagher M, Millard F, Elliott A
NPJ Precis Oncol. 2024; 8(1):249.
PMID: 39488665
PMC: 11531533.
DOI: 10.1038/s41698-024-00727-2.
Gonnet P, Marinari E, Achard V, Schaffar R, Neyroud-Caspar I, May A
Cancers (Basel). 2024; 16(20).
PMID: 39456532
PMC: 11506659.
DOI: 10.3390/cancers16203437.
Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J
Clin Cancer Res. 2024; 30(24):5593-5600.
PMID: 39417692
PMC: 11737520.
DOI: 10.1158/1078-0432.CCR-24-0606.
Novak I, Tomic M, Mulabdic D, Pezelj I, cicek S, Tomaskovic I
Biomol Biomed. 2024; 24(6):1751-1760.
PMID: 38943678
PMC: 11496859.
DOI: 10.17305/bb.2024.10745.
Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship.
Nicu A, Ionel I, Stoica I, Burlibasa L, Jinga V
Biomedicines. 2024; 12(5).
PMID: 38791003
PMC: 11117643.
DOI: 10.3390/biomedicines12051041.
The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.
Evmorfopoulos K, Marsitopoulos K, Karachalios R, Karathanasis A, Dimitropoulos K, Tzortzis V
Cancers (Basel). 2024; 16(2).
PMID: 38275869
PMC: 10814346.
DOI: 10.3390/cancers16020428.
Pure testicular choriocarcinoma, a rare and highly malignant subtype with challenging treatment: A case report and review of the literature.
Lei N, Lei L, Wang C, Mei C
Mol Clin Oncol. 2024; 20(1):1.
PMID: 38223403
PMC: 10784770.
DOI: 10.3892/mco.2023.2699.
Brain and Spinal Tumors Originating from the Germ Line Cells.
Wong T, Tsai M, Chang H, Hsieh K, Ho D, Lin S
Adv Exp Med Biol. 2023; 1405:421-455.
PMID: 37452948
DOI: 10.1007/978-3-031-23705-8_16.
Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options.
Skowron M, Kotthoff M, Bremmer F, Ruhnke K, Parmaksiz F, Richter A
Mol Med. 2023; 29(1):40.
PMID: 36991316
PMC: 10053054.
DOI: 10.1186/s10020-023-00636-3.
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Schepisi G, Gianni C, Cursano M, Galla V, Menna C, Casadei C
Front Immunol. 2023; 14:1118610.
PMID: 36860862
PMC: 9968831.
DOI: 10.3389/fimmu.2023.1118610.
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
Yu L, Sun M, Zhang Q, Zhou Q, Wang Y
Front Immunol. 2022; 13:982026.
PMID: 36159789
PMC: 9498063.
DOI: 10.3389/fimmu.2022.982026.
Overcoming Chemotherapy Resistance in Germ Cell Tumors.
Orszaghova Z, Kalavska K, Mego M, Chovanec M
Biomedicines. 2022; 10(5).
PMID: 35625709
PMC: 9139090.
DOI: 10.3390/biomedicines10050972.
Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.
Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S
Int J Urol. 2022; 29(7):741-747.
PMID: 35462438
PMC: 9545636.
DOI: 10.1111/iju.14885.
Mediastinal germ cell tumours: where we are and where we are going-a narrative review.
Marandino L, Vogl U
Mediastinum. 2022; 6:7.
PMID: 35340835
PMC: 8841536.
DOI: 10.21037/med-21-33.
Non-Epithelial Ovarian Cancers: How Much Do We Really Know?.
Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M
Int J Environ Res Public Health. 2022; 19(3).
PMID: 35162125
PMC: 8834485.
DOI: 10.3390/ijerph19031106.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K
Mol Cancer. 2022; 21(1):28.
PMID: 35062949
PMC: 8780712.
DOI: 10.1186/s12943-021-01489-2.
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
Labadie B, Balar A, Luke J
Cancers (Basel). 2021; 13(21).
PMID: 34771578
PMC: 8582522.
DOI: 10.3390/cancers13215415.
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?.
Jang A, Adler D, Rauterkus G, Bilen M, Barata P
Cancers (Basel). 2021; 13(20).
PMID: 34680214
PMC: 8533722.
DOI: 10.3390/cancers13205065.
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.
Petrelli F, Consoli F, Ghidini A, Perego G, Luciani A, Mercurio P
Front Immunol. 2021; 12:720748.
PMID: 34616395
PMC: 8488393.
DOI: 10.3389/fimmu.2021.720748.
